Synthetic DNA specialist 4basebio (LSE:4BB) reported a sharp rise in first-half sales orders and a much larger commercial pipeline, although recognised Revenue fell, and separately announced a Supply role for a pharmaceutical client's Phase I cell therapy trial alongside TriLink BioTechnologies.

What was announced

4basebio PLC (LSE:4BB), the AIM-quoted, Cambridge-based company, published two announcements on 28 September 2026. The first was its unaudited half-year report for the six months ended 30 June 2026. The second set out a Partnership under which 4basebio will supply clinical-grade opDNA synthetic DNA starting material for an unnamed multinational pharmaceutical company's Phase I cell therapy programme, with TriLink BioTechnologies acting as manufacturer of the mRNA drug substance.

Chief Executive Dr Amy Walker said that, following Investment in operational and commercial infrastructure in 2025, the first half of 2026 was a period of commercial momentum that positions the company to deliver future growth.

The numbers

Revenue fell to £0.3m from £1.2m in the first half of 2025, while sales orders rose 210% to £1.2m from £0.4m. Normalised Gross Profit was £0.19m (£0.76m). The operating loss was £8.9m (£8.3m) and the net loss for the period widened to £8.9m from £7.8m.

Net operating cash outflow was £8.4m (£8.2m). Cash at 30 June 2026 was £14.1m, down from £17.8m at 31 December 2025, after the company drew down €7m from its Loan Facility with 2Invest AG. Non-current financial liabilities stood at £22.3m and net Assets at £1.3m. The company said the drawdown extends its cash runway into late 2027.

The qualified Business pipeline stands at £63m, which the company said is a six-fold increase since the third quarter of 2025, with about 95% made up of high-quality (HQ) and GMP opportunities. 4basebio has 134 clients and has signed 28 new programmes so far in 2026. It reported executed orders of £1.4m at the date of the announcement, with £1.2m of revenue expected to be recognised over the next 12 months.

Commercial developments

During the period the company secured a clinical supply agreement for a Phase 2 trial with a cancer immunotherapy developer, formed a strategic collaboration with viral vector contract manufacturer Genezen, launched a single-stranded DNA (ssDNA) platform and extended its relationship with a Tier 1 pharmaceutical customer to support a Phase 1 cell therapy programme.

The TriLink announcement relates to cell therapy work for a multinational pharmaceutical client. 4basebio will supply opDNA, its enzymatically produced DNA template, while TriLink, part of Maravai LifeSciences, has been selected as contract development and Manufacturing organisation to produce the mRNA drug substance using its CleanCap co-transcriptional capping technology. The arrangement extends an existing relationship between 4basebio and the client. No financial terms, pricing or revenue expectations were disclosed, and the client and the therapy's indication were not named.

Chief Commercial Officer Christine Wolosin said the collaboration reflects the company's aim of offering safer and more cost-effective alternatives to plasmid DNA, while TriLink's Chad Decker, Senior Vice President of Global Sales, highlighted the consistency of combining the two technologies.

The company's Leadership now comprises Dr Walker, promoted to Chief Executive from Chief Operating Officer, Scott Lorimer as Chief Operating Officer and Richard Bungay as Chief Financial Officer, with Manja Boerman as Chairwoman.

What to watch next

According to the company's outlook, HQ and GMP orders in late-stage contracting, together with other well-progressed opportunities, are expected to "significantly increase revenue recognition in H2 2026 and 2027", and net cash outflows from operations are expected to reduce in the second half of 2026 and into 2027. The company also said it expects full-year 2026 revenue to be lower than in 2025 because of the slow first half. These are the company's own expectations. Conversion of the £63m pipeline into signed orders and the progress of the client's Phase I programme are the next milestones set out in the announcements.